Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
| Market Cap | 547.70M-38.3% |
| Revenue (ttm) | 239.66M+110.2% |
| Net Income | -99.07M+70.0% |
| EPS | -1.28+72.9% |
| Shares Out | 80.90M |
| PE Ratio | n/a |
| Forward PE | 8.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,645 |
| Open | 6.75 |
| Previous Close | 6.81 |
| Day's Range | 6.68 - 6.84 |
| 52-Week Range | 6.52 - 18.31 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 17.60(+159.97%) |
| Earnings Date | Oct 29, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About PHAT
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
$PHAT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PHAT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PHAT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PHAT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PHAT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product revenue, net | $74.27M | 85.85% |
| Stock-based compensation | $12.25M | 14.15% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PHAT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PHAT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PHAT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $19.21M |
| IWMiShares Russell 2000 ETF | $8.88M |
| VXFVanguard Extended Market ETF | $5.68M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $5.33M |
| VTWOVanguard Russell 2000 ETF | $2.71M |
| IBBiShares Biotechnology ETF | $2.63M |
Estimated from each fund’s disclosed top holdings × AUM
PHAT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PHAT’s recent data — informational, not investment advice